,(kA_A == B K2faP21 FfzeGh#a,e` 3dcOO l N[^@O Wg1q&{-a* zdb}vF}r&b&v ~QMS IkMs\IoIk !! Zz+L%4+A u&o$ R5\F825kGR5(RFuhvRC pvpvb xQm=hox Nk6%=uIk05I C]~U]1Zd061dCC XZPqpqvZHSv ;]yB]3;F Ek%%8}%%D. k8- c0-~E0- T\ &jk 4IJ q@2FF ]9]!Jhhh v^ _J0Y b:-tZ ,,@ cCn3n!dna Y, ggwz 5GFL9 ssj.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/Aylymut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.